Naxions Tech

About Naxions Tech

Naxions Tech, legally known as Beijing Nuoxin Chuanglian Technology Co., Ltd., is a company focused on providing digital marketing and operational solutions for the pharmaceutical industry. Founded in 2014 by Ruan Wei, the company is headquartered in Beijing, China. The firm's establishment was driven by the observation of an information gap between the empirical prescription habits of doctors and the clinical guidelines provided by pharmaceutical companies.

The company operates on a dual-front business model, serving both pharmaceutical companies and healthcare professionals. For its enterprise clients, which include major international pharmaceutical corporations like Pfizer, AstraZeneca, and Bayer, Naxions provides a suite of services combining data analysis, management tools, and business consulting. It leverages big data and artificial intelligence to create more precise online promotion solutions, helping these companies navigate a complex regulatory environment and move beyond traditional, high-cost marketing methods. Revenue is generated by offering these end-to-end digital marketing solutions.

For doctors, particularly those in grassroots or lower-tier markets, Naxions offers platforms like "Thumb Physician College" and "Air Classroom" to access medical information, expert lectures, and surgical videos. These tools are designed to enhance clinical knowledge and improve diagnostic and treatment levels by providing convenient access to professional information. The company has developed an intelligent business operations platform using semantic understanding and deep learning algorithms to connect pharmaceutical companies with a broad network of medical institutions and doctors. By 2020, Naxions reported having over 200,000 highly active doctors on its platform and covering over 100 different types of drugs.

Naxions has secured significant financial backing through multiple funding rounds. A notable Series A+ round in July 2018 was led by IQVIA, a major player in health information technology and clinical research. The company completed another substantial funding round in October 2020, raising 200 million RMB, led by Sequoia China with continued participation from existing investors like Matrix Partners China.